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Summary The interaction between laminin and the oncoprotein encoded by the c-erbB-2 oncogene was
studied in vitro and in vivo in human breast carcinomas. In vitro analysis of breast carcinoma cell lines
overexpressing p185HER2 revealed that laminin, but not fibronectin, induced tyrosine phosphorylation and
down-modulation of oncoprotein membrane expression. Laminin also specifically inhibited growth of
pl85HER2_positive cell lines. No direct binding between the recombinant extracellular domain of pl85HER2
and laminin was found. Induction of oncoprotein down-modulation by anti-integrin antibodies and
coprecipitation of the oncoprotein with the fl4 integrin subunit indicate that the interaction between
p185HER2 and laminin occurs through integrin molecules. The relevance of this in vitro observation was verified
in vivo by analysing the prognostic value of p185HER2 overexpression as a function of laminin production on
archival paraffin-embedded sections of 887 primary breast tumours. The results revealed an association between
pl85HER2 overexpression and unfavourable prognosis in tumours negative for laminin production, whereas in
laminin-producing tumours, the oncoprotein overexpression was not associated with tumour aggressiveness.
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The c-erbB-2 proto-oncogene encodes a transmembrane
glycoprotein of 185 kDa (pl85HER2) with intrinsic tyrosine
kinase activity and close homology with the epidermal
growth factor (EGF) receptor (Coussens et al., 1985).
Amplification of the c-erbB-2 gene and overexpression of its
product induce cell transformation (Di Fiore et al., 1987) and
have been associated with poor prognosis in different
tumours of epithelial origin (Rilke et al., 1991; Berchunck
et al., 1990; Kern et al., 1990; Gullick, 1990; Slamon et al.,
1989). Monoclonal antibodies (MAbs) directed to pl85HER2
(Hurwitz et al., 1995; Stancovski et al., 1991; Tagliabue et al.,
1991; Hudziak et al., 1989; McKenzie et al., 1989), as well as
different candidate ligands of the p185HER2 receptor (Samanta
et al., 1994; Huang et al., 1992; Wen et al., 1992; Holmes et
al., 1992; Peles et al., 1992; Dobashi et al., 1991,
Tarakhovsky et al., 1991; Lupu et al., 1990; Yarden et al.,
1989) and oestrogen (Matsuda et al., 1993), have been shown
either to stimulate or to inhibit cell growth. c-erbB-2 can also
be activated by interaction with other activated members of
the EGF receptor family. Ligand-dependent activation of the
EGFR, c-erbB-3 or c-erbB-4 by EGF or heregulin/neu-
differentiating factor (HRG/NDF) have been shown to
result in heterodimerisation and, thereby, activation of c-
erbB-2 (Tzahar et al., 1994; Kita et al., 1994; Carraway et al.,
1994; Plowman et al., 1993b; Connelly et al., 1990). In some
cell lines, HRG/NDF can also induce differentiation (Peles et
al., 1992; Bacus et al., 1992).
We have recently shown (Campiglio et al., 1994) that a6f4
integrin capping, induced by anti-integrin MAbs, also gives
rise to p185HER2 clustering and tyrosine phosphorylation of
this receptor. Laminin, the ligand ofthe a6,B4 receptor (Lee et
al., 1992), increases the basal level of pl85HER2 phosphoryla-
tion (Campiglio et al., 1994), suggesting a role for adhesion
molecules in the activation of the oncoprotein.
In the present study, we investigated the effects of soluble
laminin on pl85HER2 activation and expression in breast
carcinoma cell lines overexpressing the oncoprotein. To verify
the relevance of the in vitro observations on in vivo tumour
aggressiveness, we also evaluated the prognostic value of c-
erbB-2 overexpression relative to laminin production in a
series of 887 primary breast carcinomas.
Materials and methods
Cells and culture conditions
Human breast carcinoma cell lines SKBr3, MDA MB453 and
MCF-7 (ATCC, Rockville, MD, USA) were maintained in
RPMI-1640 (Sigma Chemical Co., St Louis, MO, USA) with
5% fetal calf serum (FCS) supplemented with penicillin
(100 mg ml-') and streptomycin (100 mg ml-').
For the proliferation assay, cells were seeded at a density
of 250 x 103 per well in triplicate 6-well plates in the presence
or absence of exogenously added adhesion molecules
(50 pg ml-'). After 4 days, cells were trypsinised and
counted under the light microscope. Murine laminin,
purified from mouse Engelbreth Holm Swarm tumour cells,
and human fibronectin, purified from plasma, were obtained
from Sigma and Boehringer Mannheim (Germany) respec-
tively.
Flow cytometric analysis
Antigens expressed by laminin-treated cells were quantitated
by indirect immunofluorescence with fluorescein isothiocya-
nate-conjugated goat anti-mouse Ig (Kirkegaard and Perry
Laboratories Inc., Gaithersburg, MD, USA) and the
following purified MAbs: MGR2, directed against the
extracellular domain of p185HER2 (Tagliabue et al., 1991);
MGR1, directed against the extracellular domain of the EGF
receptor (Pellegrini et al., 1991); and W6/32, directed against
a monomorphic determinant of human HLA-A,B,C mole-
cules (Parham et al., 1979). Fluorescence intensity was
measured using a FACScan flow cytometer with LISYS II
software (Becton Dickinson, Mountain View, CA, USA).
Analysis of oncoprotein tyrosine phosphorylation
Breast carcinoma cells treated with laminin for 5 min were
lysed using non-ionic detergent (1% NP40 in 50 mM Tris-
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HCl, pH 7.4) in the presence ofphosphatase inhibitors (1 mM
sodium orthovanadate) and 2 mg of lysate was immunopre-
cipitated with MAb MGR2. Immunoprecipitates were
subjected to immunoblot analysis with anti-P-Tyr MAb
(4 ug ml-') (Upstate Biotechnology, Inc., Lake Placid, NY,
USA) and with MAb c-neu Ab3 (1 pg ml-'), which
specifically detects the p185HER2 carboxy-terminal peptide
(Oncogene Science, Inc. Manhasset, NY, USA).
Extracellular domain (ECD) treatment
The human c-erbB-2 receptor extracellular domain (ECD)
was produced using the baculovirus expression system
(Luckow et al., 1989). A 2 kb cDNA encoding amino acids
1 to 622 of the erbB-2 protein (Akiyama et al., 1986) was
cloned into the expression transfer vector pVL1393 using
SmaI and XbaI cloning sites. Stop codons were inserted at
the 3' end of the ECD coding sequence. The protein was
expressed in Sf9 cells and purified from the culture medium 4
days after infection with the recombinant virus. Recombinant
protein (20 pg) purified by immunoaffinity chromatography
was labelled with 1251I by the Bolton-Hunter reagent
(Amersham, Little Chalfont, UK). The functionality and
specificity of the labelled molecule were assessed in a binding
assay using polystyrene beads coated with MAbs MGR2 and
MGR4 against the oncoprotein ECD (Centis et al., 1992;
Tagliabue et al., 1991), or with an unrelated MAb
(Martignone et al., 1992). Binding of labelled ECD was
assayed in wells of 96-well plates adsorbed with laminin,
fibronectin, bovine serum albumin (BSA) or MAb MGR2 at
a concentration of 10 pg per well.
Co-immunoprecipitation
MDA MB453 breast carcinoma cells were treated with
laminin (50 pg ml-') for 5 min and lysed in the absence of
ionic detergent. Lysate (2 mg) was immunoprecipitated with
the following MAbs: MAR4 directed against the P1 integrin
subunit (Pellegrini et al., 1992); and 3E1 directed against the
#4 integrin subunit (Telios, San Diego, CA, USA).
Immunoprecipitates were subjected to immunoblot analysis
with MAb c-neu Ab3 (Oncogene Science), and the proteins
were visualised with the ECL detection system (Amersham).
Filters were stripped in a buffer containing 62.5 mM Tris-HCl
(pH 6.8), 2% sodium dodecyl sulphate (SDS) and 100 mM p-
mercaptoethanol for 30 min at 65°C and reprobed with the
indicated antibodies.
Surgical specimens
Paraffin-embedded tissues obtained surgically from 887
patients with breast cancer and collected in our Institute
from January 1968 to December 1971 were examined. In
patients with histologically positive axillary lymph nodes,
surgery was combined with subsequent radiotherapy on
supraclavicular and internal mammary lymph nodes. No
systemic treatment was administered until the time of
relapse.
Immunohistochemical analysis
Rabbit polyclonal antibodies directed against p185HER2
(kindly provided by Dr DJ Slamon, UCLA School of
Medicine, Los Angeles, CA, USA) (1:500), and rabbit
antiserum directed against human laminin (Telios, San
Diego, CA, USA) (1:100) were used. The immunoperoxidase
test was carried out on paraffin-embedded sections using the
avidin-biotin-peroxidase complex (ABC) kit (Vector,
Burlingame, CA, USA).
Statistical analysis
Overall survival of patients from the date of surgery was
evaluated, considering only deaths from breast cancer as
events. Survival rates were evaluated using the actuarial life-
table approach. The log-rank method was used to analyse the
differences in survival curves.
Results
In vitro analysis ofpJ85HE" and laminin interaction
Three cell lines, two overexpressing c-erbB-2 (SKBr3 and
MDA MB453) and one not expressing the oncogene (MCF-
7), were cultured in the presence of laminin or fibronectin for
4 days and tested for expression and activation of the c-erbB-
2 oncoprotein. Laminin induced a down-modulation of the
membrane expression of the oncoprotein as compared with
untreated or fibronectin-treated cells on the two cell lines
overexpressing p185HER2, whereas no change was found for
MCF-7 cells, which do not express this oncoprotein (Figure
a)
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Figure 1 Cytofluorimetric analysis of p185HER2 expression in
SKBr3 (a and b), MDA MB453 (c and d) and MCF-7 cells (e and
f) incubated with (bold line) or without (light line) laminin (a, c
and e) or fibronectin (b, d, and f). Dotted lines show background
values.
Table I Effect oflaminin on membrane marker expression in breast
carcinoma cells
Marker
Treatment fluorescence
with intensitya
Cell line laminin pI85HER2 EGFR HLA
SKBr3 - 524+164 98+20 20+5
+ 96+30b 96+15 20+3
MDA MB 453 - 326+114 42+13 57+10
+ 130+52b 45+10 55+12
MCF-7 - 29+8 21+5 118+23
+ 27+5 23+7 108+19
aMean fluorescence intensity ±s.d. obtained from five experiments
by immunofluorescence assay and FACScan analysis. bStatistically
significant decrease determined using Student's t-test.
M
-
L nI1). This down-modulation induced by laminin was repro-
ducible and significant, whereas no effect on EGFR and class
I HLA expression was observed (Table I). Time course
analysis of pl85HER2 down-modulation revealed decreased
oncoprotein expression on the cell surface of p185HER2_
overexpressing cell lines after 1 h of laminin treatment, with
further down-modulation until 4 days, when decreased
p185HER2 expression plateaued (Figure 2).
To determine whether the rapid membrane down-
modulation of oncoprotein was associated with activation
of p185HER2, the state of receptor tyrosine phosphorylation
was determined in the same cell lines treated or not with
soluble laminin. As detected by immunoblot analysis of anti-
p185HER2 immunoprecipitates with anti-P-Tyr antibodies,
tyrosine phosphorylation of oncoprotein was increased in
SKBr3 cells after treatment with soluble laminin (Figure 3).
A smaller, but still significant, increase was observed in MDA
MB453 cells after the same treatment (data not shown).
Proliferation assay of different breast carcinoma cells
grown in the presence of 50 ug ml-' laminin or fibronectin
for 4 days indicated that laminin, but not fibronectin, induces
a 40% inhibition of cell growth in both cell lines
overexpressing p185HER2 (SKBr3 and MDA MB453),
whereas no variation was found for MCF-7 cells (Figure 4).
Analysis to determine whether the two molecules interact
directly indicated no binding of radiolabelled p185HER2 ECD
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to laminin or to fibronectin and BSA used as negative
controls, whereas the same labelled molecule was recognised
by a MAb directed against the p185HER2 ECD (Figure 5).
Based on the observed colocalisation of pl85HER2 and the
a6,B4 integrin receptor in a lung carcinoma cell line
(Campiglio et al., 1994), the possibility of an indirect
interaction mediated by this integrin receptor was investi-
gated. The down-modulation of oncoprotein membrane
expression was analysed in SKBr3 and MDA MB453 cells
after treatment with MAb GoH3 (Immunotech, Inc.,
a
1400
m 0)
V- 1200
x
= 1000
% 800 .SBo
.a 600
E
= 400
200
U IL- L
MCF-7 SKBr3
J
MDA MB 453
0min I h 3h 24h 48h 96h
Time
Figure 2 Cytofluorimetric analysis of p185HER2 down-modula-
tion as a function of duration of laminin treatment of SKBr3
( [I), MDA MB453 ( =Z) and MCF-7 (B) cells.
Figure 4 Effect of laminin (a) or fibronectin (b) on breast
carcinoma cell proliferation. Proliferation in medium alone (LI)
or in medium containing exogenous adhesion molecules (M).
Values are the mean+s.d. of three separate experiments.
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Figure 3 Tyrosine phosphorylation ofp185HER2 as a function of
laminin treatment. Immunoblot with anti-P-Tyr and c-neu Ab3
MAbs of anti-pI85HER2 immunoprecipitates from SKBr3 cells
incubated with or without laminin.
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Figure 5 Binding of labelled extracellular domain (ECD) of
pl85HER2 to laminin (0), fibronectin (-), BSA (A) or MAb
MGR2 (V).
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Westbrook, ME, USA), which is directed against the laminin
binding site of the a6 integrin subunit. Laminin and the anti-
o6 MAb each induced a significant (P<0.05) decrease in
Table II Expression of p185HER2 in breast cancer cell lines treated
with MAb GoH3, laminin or both
Cell line Treatment Fluorescence intensitya
SKBr3 570+ 102
GoH3 266+33b
LN 130+42b
GoH3 + LN 142+35b
MDA MB453 350+91
GoH3 190+42b
LN 135+27b
GoH3+LN 119+50b
aMean fluorescence intensity ±s.d. obtained from three experiments
by immunofluorescence assay and FACScan analysis. bStatistically
significant (P<0.05) as determined using Student's t-test.
pl85HER2 membrane expression, and no further down-
modulation was observed when cells previously treated with
GoH3 were seeded in the presence of laminin (Table II).
To investigate the mechanism of interaction between
laminin and p185HER2 further, fresh lysates, obtained from
MDA MB453 cells treated with laminin or untreated, were
subjected to immunoprecipitation with MAbs to #1 and /4
integrin subunits and immunoblotted with an anti-pl85HER2
MAb. As shown in Figure 6, the oncoprotein was recovered
from ,B4 immunoprecipitates and the amount of coprecipi-
tated p185HER2 was slightly increased in cells treated with
laminin. No oncoprotein was detectable in the material
immunoprecipitated with #1 antibodies.
In vivo analysis ofprognostic value ofpJ85HER2
Immunohistochemical analysis of archival paraffin-embedded
sections of 887 primary breast carcinomas indicated p185HER2
overexpression and laminin production in 22% and 27% of
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Figure 6 Western blot analysis of anti-,l and anti-,B4
immunoprecipitates from MDA MB453 cells incubated with or
without laminin using c-neu Ab3 MAb. Filters were stripped and
reprobed with anti-fl1-or anti-,B4-specific antibodies.
Figure 8 Survival rates of patients with primary breast
carcinomas according to p185HER2 overexpression and laminin
production. This includes 176 p185HER2-negative, laminin-positive
cases (A), 68 p185HER2_positive, laminin-positive cases (Y), 514
p185HR -negative, laminin-negative cases (f), 129 pl85HER2_
positive, laminin-negative cases (0).
Figure 7 Immunohistochemical analysis performed on paraffin-embedded sections of breast carcinoma with polyclonal serum against
p185HER2 (a) or against laminin (b), or negative control serum (c).
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the cases respectively. All of the 197 cases that overexpressed
p185HER2 showed a characteristic staining at the cell
membrane level (Figure 7a). Tumours were considered
laminin positive (244 cases) when they displayed staining at
the membrane and/or cytoplasmic level (Figure 7b). Laminin
production by itself was not found to be associated with any
other prognostic factors, such as nodal status, tumour size
and grading (Pellegrini et al., 1995). Survival curves showed a
strong correlation between poor prognosis and p185HER2
overexpression (P<0.01), whereas laminin production per se
had no impact on survival. However, when these two
parameters were analysed together, the prognostic value of
the oncoprotein was significantly influenced by laminin
production (Figure 8). For patients with laminin-negative
tumours (643 cases), p185HER2 overexpression was signifi-
cantly associated with poor prognosis (P <0.01). By
contrast, no statistically significant differences in survival
rate as a function of p185HER2 overexpression were found in
patients with laminin-producing tumours (244 cases).
Discussion
The present study shows that laminin, a molecule of the
extracellular matrix, can functionally interact with the c-
erbB-2 oncoprotein. In vitro laminin treatment of breast
carcinoma cells overexpressing p185HER2 resulted in activation
of the oncoprotein as measured by tyrosine phosphorylation,
down-modulation of membrane expression and, ultimately,
inhibition of cell proliferation. The survival data for breast
cancer patients clearly indicate the relevance of this
interaction in the proliferation of in vivo human tumours,
since p185HER2 overexpression, which is strongly associated
with poor prognosis in laminin-negative tumours, almost
completely lost its prognostic significance in laminin-
producing tumours.
No direct binding between laminin and the c-erbB-2
oncoprotein was detected, suggesting that their interaction is
mediated by other molecules. Indeed, the decrease in
p185HER2 membrane expression upon treatment with an
anti-a6 MAb strongly suggests that the interaction is
mediated through laminin-specific integrins. Consistent with
this suggestion, coprecipitation of c-erbB-2 with the ,B4
subunit demonstrates that these molecules are structurally
associated on the cell membrane, and their association is
increased and stabilised by laminin binding. The interaction
appears to be restricted to the /4 integrin, since no
oncoprotein was found associated with the /1 integrin. The
interaction of laminin integrins induces receptor clustering at
the plasma membrane and consequent activation ofp185HER2.
Up-regulation of membrane protein tyrosine phosphorylation
by integrin clustering has been reported (Kornberg et al.,
1991), and our recent study in which clustering of the a6#4
integrin receptor in a lung carcinoma cell line was shown to
enhance tyrosine phosphorylation of overexpressed pl85HER2
(Campiglio et al., 1994) indicates an activation of this
oncoprotein in the presence of laminin. Overexpression of
p185HER2 at the tumour cell surface is generally thought to
lead to a growth-promoting signal (Di Fiore et al., 1987), and
p185HER2 uses a signal transduction pathway that is localised
at the plasma membrane level (Aronheim et al., 1994; Ben-
Levyet al., 1994). The laminin-induced removal of pl85HER2
from the cell surface may result in decreased growth of those
tumour cells that overexpress this receptor. Consistent with
the hypothesis that the oncogenic potential of p185HER2 is
restricted to the membrane form, antibody-mediated inter-
nalisation of this receptor was associated with inhibition of
tumour growth (Hurwitz et al., 1995). Moreover, a
cytoplasmic localisation of c-erbB-2 in breast carcinomas
has been linked to better prognosis compared with tumours
that showed cell membrane localisation of this receptor
(Zschiesche et al., 1994).
However, the possibility remains that laminin, upon
interacting with integrins, becomes available for binding to
other molecules of the HER family that are normally not
involved in such a phenomenon owing to insufficient binding
affinity. Indeed, heregulin, the ligand for c-erbB-3 and c-erbB-4
(Tzahar et al., 1994; Sliwkowski et al., 1994; Plowman et al.,
1993b), represents a family of molecules sharing an EGF-like
domain, which appears to be responsible for receptor
recognition (Panayotou et al., 1989; Holmes et al., 1992; Wen
et al., 1992). Similar EGF-like domains are also present in the
short arms oflaminin (Sasaki et al., 1987; Sasaki and Yamada,
1987). Assuming that EGF-like regions in different proteins are
an essential motif for protein-protein interaction, the
corresponding domain of laminin might be responsible for
the interaction of this adhesion molecule with members of the
HER receptor family. In fact, the interaction only with
integrins does not explain the differences between SKBr3 and
MDA MB453 cells in level ofactivation, since the latter, which
are less responsive to laminin, actually express a higher amount
of oc6,B4 integrin than do SKBr3 cells, but show a different
pattern of HER family molecules (Plowman et al., 1993a;
Kraus et al., 1993; King et al., 1988).
No morphological evidence ofcell differentiation, which has
been reported to occur when p185HER2 activation leads to cell
growth inhibition (Peles et al., 1992; Bacus et al., 1992), was
observed after laminin treatment ofcells. However, SKBr3 and
MDA MB453 cells have a high level of aneuploidy, which
might prevent a clear response to differentiation stimuli.
Although the interaction between laminin and pl85HER2
occurs by an indirect mechanism, the in vitro and in vivo data
demonstrate the importance of this interaction for tumour
progression. These data may open new approaches to
therapeutic intervention of breast carcinoma that exploit the
ability of laminin to reduce p185HER2-related tumour aggres-
siveness. For this, agents that up-regulate laminin production
by the tumour or laminin-derived peptides might be suitable.
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